TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Effectiveness and Impact on Health-related Quality of Life in Peruvian Patients With Psoriasis After 16 Weeks of Adalimumab Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Participants with moderate to severe chronic plaque psoriasis defined as Psoriasis Area and Severity Index (PASI) ≥ 10 and body surface area ≥ 10% with or without psoriatic arthritis, who have an adalimumab therapy indication because they are candidates for systemic therapy or phototherapy and other systemic therapies are medically less appropriate~* Participant is capable of and willing to give written informed consent and to comply with the requirements of the study protocol~Exclusion Criteria:~* Participants should not be enrolled if they cannot be treated in accordance with the local product label~* Participants enrolled into another study or clinical trial~* History of hepatitis B infection~* History of neurologic symptoms suggestive of central nervous system demyelinating disease~* History of cancer or lymphoproliferative disease (other than successfully treated non-melanoma skin cancer or localized carcinoma in situ of the cervix)~* Active tuberculosis infection before initiating adalimumab treatment or latent tuberculosis infection not able to take complete prophylactic treatment~* Pregnant or lactating female, demonstrated by a pregnancy test before entering the study and willing to use a contraceptive method~* Use of another anti-tumoral necrosis factor previously~* History of congestive heart failure~* Any other condition that according to the criteria of the participating investigator represents an obstacle for study conduction and/or subjects participants to an unacceptable risk~* Participants with active infection including chronic or localized infections until infections are controlled~* History of sensitivity to latex~* Participants who will receive concomitant phototherapy and systemic therapy during adalimumab therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Adalimumab Treatment in Participants with Psoriasis (Type: None): Participants with moderate to severe chronic plaque psoriasis defined as Psoriasis Area and Severity Index (PASI) ≥ 10 and body surface area ≥ 10% with or without psoriatic arthritis, who have an adalimumab therapy indication because they are candidates for systemic therapy or phototherapy and other systemic therapies are medically less appropriate.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase II Trial of Stereotactic Body Radiotherapy Followed by Ipilimumab in Treating Patients With Stage IV Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed diagnosis of melanoma~* Previously treated or previously untreated stage IV melanoma by American Joint Committee on Cancer (AJCC) staging criteria~* Presence of an index lesion between 1 and 5 cm~* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2~* Signed informed consent document~* Adequate renal, hepatic, and hematologic indices for ipilimumab therapy~* Ability to tolerate stereotactic body radiation therapy (e.g. lie flat and hold position for treatment)~Exclusion Criteria:~* Prior systemic therapy within 14 days of study enrollment; patients must be adequately recovered from prior systemic therapy side effects as deemed by the treating investigator~* Clinical contraindication to stereotactic body radiotherapy (e.g. active systemic sclerosis, active inflammatory bowel disease if bowel is within target field, etc)~* Presence of central nervous system metastasis (including active brain metastasis); active brain metastasis would be defined as untreated brain metastases; if the brain metastases have received prior treatment (usually either with surgery or radiation), they are no longer active~* Long-term use of systemic corticosteroids; patients with replacement steroids and not immunosuppressive steroids may enroll in the study~* Prior radiation therapy (RT) that precludes the delivery of SBRT

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (stereotactic body radiotherapy, ipilimumab) (Type: EXPERIMENTAL): Patients undergo a total of 3 fractions of stereotactic body radiotherapy between days 1-13. Patients then receive ipilimumab IV every 3 weeks. Treatment repeats every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Urea for Chronic Hyponatremia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥18 years~* Attended ≥1 visit at a University of Pittsburgh Medical Center (UPMC) outpatient clinic within the prior 12 months~* Chronic hyponatremia with a history of ≥ 2 sequential plasma sodium concentration (PNa) between 125 mmol/L and 132 mmol/L performed ≥ 14 days apart within the last 12 months with most recent PNa ≤ 132 mmol/L prior to screening~* Patients are ambulatory without the need for any assist device (e.g., cane, walker)~* Mini-mental state examination (MMSE) score ≥ 25~* Diagnosis of SIADH established by the Bartter and Schwartz criteria as follows:~  1. Hyponatremia with a PNa between 125 mmol/L and 132 mmol/L~ 2. Plasma osmolality \< 275 mOsm/kg~ 3. Clinical euvolemia~ 4. Urine osmolality \> 100 mosm/kg~ 5. Urine Na ≥ 20 mmol/L~ 6. Intact adrenal function (i.e., morning plasma cortisol value ≥15 μg/dL, or negative corticotropin stimulation test)~ 7. Normal thyroid stimulating hormone (TSH) level (i.e., TSH between 0.3 to 5 μIU/mL)~ 8. eGFR \>= 45 ml/min/1.73 m2)~Exclusion Criteria:~* Cirrhosis and/or end-stage liver disease~* Heart failure on diuretics and/or with recorded left ventricular ejection fraction \<40 percent~* Chronic kidney disease with most recent estimated glomerular filtration rate \<45 ml/min/1.73m2~* Adrenal insufficiency~* Untreated hypothyroidism~* Urinary tract obstruction within the prior 2 months~* Uncontrolled hyperglycemia (most recent random plasma glucose ≥ 200 mg/dL)~* Ongoing drug treatment for hyponatremia with vaptans or combination of loop diuretics and salt tablets.~* Active malignancy~* Active infection~* Neurological disorders with impairment of ambulation or cognition~* End-stage lung disease with marked impairment in ambulatory capacity~* Chronic pain with impairment of ambulation or cognition~* Chronic nausea~* Hypersensitivity to urea~* Women who are pregnant, breast feeding, or of childbearing potential who are not using contraception~* Patient is unable to consent for himself/herself

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- On Urea, Then Off Urea (Type: EXPERIMENTAL): Participants assigned to this group will receive oral urea for 42 days (period 1), followed by a 10-day washout period, and then will be off urea for 42 days (period 2).
- Off Urea, Then On Urea (Type: EXPERIMENTAL): Participants assigned to this group will be off urea during for 42 days (period 1), followed by a 10-day washout period, and then on urea for 42 days (period 2)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven glioblastoma~* Stable disease following ≥ 4 cycles of adjuvant temozolomide~* No progression or recurrence of disease~PATIENT CHARACTERISTICS:~* HLA-A\*02 positive~* ≥ 18 years old~* Life expectancy \> 8 weeks~* Karnofsky performance status ≥ 60~* WBC \>3,500/µL~* ALC \>350/mm3~* ANC \>1,500/mm3~* Platelet count \>100,000/mm3~* Hemoglobin \>10gm/dL~* AST, ALT and alkaline phosphatase \<2.5 times upper limit of normal (ULN)~* Bilirubin \<1.5 times ULN~* Creatinine \<1.5 mg/dL and/or creatinine clearance \>60cc/min~* Serum potassium, magnesium and calcium within normals levels (supplementation is allowed)~* Not pregnant or nursing~* Negative pregnancy test~* Practice birth control during and for 2 months after treatment with IMA950 (both genders)~* Women of childbearing age must agree to use adequate contraceptive methods~* No significant active hepatic, renal, infectious or psychiatric disease~* No HIV, active hepatitis infection, or any other active severe infectious disease~* No history of autoimmune disease or immunosuppression~* No clinically significant cardiovascular event within 3 months before study entry or an increased risk for ventricular arrhythmia~* No malignancy other than glioblastoma that required treatment during the last 12 months~PRIOR and/or CONCURRENT THERAPY:~* See Disease Characteristics~* Completed radiotherapy and at least 4 cycles of adjuvant temozolomide~* Not be receiving steroids OR be on stable dose of steroids for ≥ 5 days prior to registration~* No other prior immunotherapy for glioblastoma~* No major surgery within 4 weeks prior to treatment start~* At least 4 weeks from cytotoxic therapies (incl. temozolomide)~* At least 2 weeks from non-cytotoxic therapies (e.g. interferon, tamoxifen)~* At least 3 weeks from bevacizumab~* No current treatment with imiquimod; prior use of imiquimod is allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Using Magnetic Resonance Imaging (MRI) to Guide Differential-Dose Prostate Brachytherapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical stage ≤ T2b according to the American Joint Commission on Cancer 6th Edition28~* PSA ≤ 15 ng/ml~* Gleason sum on biopsy ≤ 6 or 3+4=7~* Prostate volume ≤ 60 cc~* Willing to continue follow-up for at least two years~Exclusion Criteria:~* Prior hormone therapy~* Prior radiotherapy~* History of collagen vascular disease~* History of inflammatory bowel disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pre-implant MRI images and planning (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Terlipressin Administration in Patients Undergoing Major Liver Resection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing resection of 3 or more liver segments~* Minimum age of 18~* Any gender~* Written informed consent~Exclusion Criteria~* Preoperative renal failure (GFR \< 50ml/min)~* Severe liver dysfunction (Child-Turcotte-Pugh grade C)~* Hyponatremia (\<132mmol/l)~* Severe aortic regurgitation, severe mitral regurgitation, heart failure~* Symptomatic coronary heart disease~* Bradycardic arrhythmia (heart rate \< 60/min)~* Peripheral artery occlusive disease (clinical stadium II-IV)~* Dilatative arteriopathy, history of subarachnoidal bleeding~* Decompensated arterial hypertension (Blood pressure \>160/100mmHg despite intensive treatment)~* Present or suspected acute mesenteric ischemia~* Septic shock~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Terlipressin (Type: ACTIVE_COMPARATOR): Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
- NaCl (Type: PLACEBO_COMPARATOR): Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Study of Automated Care Pathway for Patients With Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients 18 years old or greater admitted to the Hospital Medicine service at UCSF Medical Center who meet criteria as determined by predictive model to be likely admissions for COPD exacerbation.~Exclusion Criteria:~* Patients admitted to other clinical services at UCSF Medical Center.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Usual care and order set A (Type: NO_INTERVENTION): Usual care. Providers may still search for a COPD order set, and in this arm will see version A, the static list of orders, which is the current state.
- Usual care and order set B (Type: ACTIVE_COMPARATOR): Usual care in the sense that COPD orders are not automatically included in admission orders despite likelihood of a COPD admission based on the predictive model. However, providers may still search for a COPD order set, and in this arm will see version B, the dynamic list of orders that has been end user tested prior to launch.
- Automatic inclusion and order set A (Type: ACTIVE_COMPARATOR): COPD order set is automatically included in admission orders as a static list.
- Automatic inclusion and order set B (Type: ACTIVE_COMPARATOR): COPD order set is automatically included in admission orders as a dynamic and end user tested version.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must have histologically documented AML, ALL, MDS, CML,~* Identification of haploidentical donor~* LVEF \> 45% corrected~* DLCO \> 50% predicted~* Serum Creatinine \<= 2 mg/dL~* Bilirubin \< 2 x ULN~* AST, ALT \< 2 x ULN~* Age ≤ 65 years~* Performance Status 0-1~Exclusion Criteria:~* Patients relapsing \<6 months after autologous SCT are not eligible.~* Patients with active infections requiring oral or intravenous antibiotics are not eligible for enrollment until resolution of infection~* No HIV disease~* Non-pregnant and non-nursing

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Alloreactive NK cell infusion (Type: EXPERIMENTAL): Escalating doses of alloreactive NK cells.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation and Medico-Economic Study of FIBROSCAN in Patients With Viral Hepatitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Chronic hepatitis B or C~* With liver biopsy indication~* Patient information~Exclusion Criteria:~* Drug hepatitis~* Metabolic hepatology~* Steatosis or non-alcoholic steatohepatitis~* Autoimmune hepatopathy~* Non-contraindication to liver biopsy~* Non-contraindication to FIBROSCAN examination~* Ascites~* Obesity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Therapeutic Strategies in Acromegalic Subjects Treated With Lanreotide 120mg

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 years or more, suffering from acromegaly~* Treatment naïve or treated subject (whatever the previous treatments except Lanreotide 120mg and radiotherapy) who does not achieve biochemical control in the physician's opinion. Requiring a treatment with Somatostatin analog (SSA)~* Having performed a Magnetic Resonance Imaging (MRI) to evaluate the tumor size within the previous 12 weeks (post-surgery MRI for operated subjects)~* In whom the physician has already decided to initiate a treatment with Lanreotide 120mg as a monotherapy~Exclusion Criteria:~* Subject previously/currently treated with Lanreotide 120mg~* History of radiotherapy for acromegaly~* Subject who requires a surgical intervention for relief of any sign or symptom associated with tumor compression~* Concomitant prolactin hypersecretion requiring a treatment with dopaminergic agonists~* Active neoplastic disease

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Prioritising Prevention of COVID-19 in Persons With Cancer in the French West Indies

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or older living in the French West Indies~* Patient with prevalent cancer of the prostate, breast, lung, colon or rectum~* Patients who receive the information leaflet and do not express any opposition to the use of their personal medical data~Exclusion Criteria:~* Patients who are unable to answer the study questionnaires~* Patients who do not speak fluent French~* Persons under legal protection

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Patients (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: ArmeoSenso - Reward

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* stroke survivor (max. 100 days post-stroke)~* upper extremity motor deficits~* patient can lift the paretic arm against gravity~* patient can move the hand at least 20x20 cm in a horizontal plane~* patient is able and willing to participate~* patient has signed informed consent~Exclusion Criteria:~* severe aphasia (impairing verbal instructions)~* severe dementia (impairing the capability to understand instructions)~* severe depression (impairing motivation to train)~* relevant (in the judgement of the investigator) impairment of visual perception, (impairing perception of goals and feedback on the computer screen)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- high incentive (Type: EXPERIMENTAL): game version including visual effects and monetary rewards
- low incentive (Type: ACTIVE_COMPARATOR): game version without visual effects or monetary rewards

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy